Sanofi: positive intermediate data for THOR-707
(CercleFinance.com) - Sanofi has reported last-minute interim clinical data validating the "non-alpha" profile of THOR-707 (SAR444245), its new experimental IL-2, in a first trial in people evaluating it as monotherapy and in combination with an anti-PD-1.
The early clinical results support those of preclinical studies and suggest that THOR-707 may induce an anti-tumor immune response, without the alpha chain mediated side effects.
THOR-707 is in clinical trials in adults with advanced or metastatic solid tumors. This interim data will be presented in a late-breaking poster session at the AACR Annual Meeting.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The early clinical results support those of preclinical studies and suggest that THOR-707 may induce an anti-tumor immune response, without the alpha chain mediated side effects.
THOR-707 is in clinical trials in adults with advanced or metastatic solid tumors. This interim data will be presented in a late-breaking poster session at the AACR Annual Meeting.
Copyright (c) 2021 CercleFinance.com. All rights reserved.